Sustained PFS Benefit of Imlunestrant Over SoC in Patients with ESR1-mutated Advanced Breast Cancer By Ogkologos - December 19, 2025 58 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from an updated analysis of the EMBER-3 study Source RELATED ARTICLESMORE FROM AUTHOR Nivolumab Added to Cisplatin and Radiotherapy Improves DFS in Patients with High-Risk Resected Locally Advanced SCCHN EMA Recommends Granting a Marketing Authorisation for Aumolertinib FDA Approves Niraparib and Abiraterone Acetate Plus Prednisone for BRCA2-mutated Metastatic Castration-Sensitive Prostate Cancer MOST POPULAR Commemorating the Contributions of Cancer Research Greats March 12, 2021 Discovery of Tumor Suppressor Suggests New Cancer Treatment Strategies May 14, 2021 Activity and Safety of Atezolizumab Combined with Carboplatin and Pemetrexed in... August 30, 2023 Can Acupuncture Help Cancer Survivors with Chronic Pain? April 22, 2021 Load more HOT NEWS Promising pCR Rates with Neoadjuvant Durvalumab Plus Platinum-based Chemotherapy Combined with... Belantamab Mafodotin–Containing Triplets Confer a Significant PFS Benefit Among Previously Treated... Can Cancer Symptoms Be Mistaken for Menopause? Ralph, Medical Dog, Retires From Colorado Children’s Hospital To Focus On...
